0001225208-18-007160.txt : 20180403 0001225208-18-007160.hdr.sgml : 20180403 20180403161259 ACCESSION NUMBER: 0001225208-18-007160 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180401 FILED AS OF DATE: 20180403 DATE AS OF CHANGE: 20180403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eddy Jodi Euerle CENTRAL INDEX KEY: 0001734900 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 18733479 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC CORPORATION STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 3 1 doc3.xml X0206 3 2018-04-01 0 0000885725 BOSTON SCIENTIFIC CORP BSX 0001734900 Eddy Jodi Euerle 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 SVP and CIO Common Stock 14203.0000 D Deferred Stock Units 2019-01-02 Common Stock 2099.0000 D Deferred Stock Units 2021-02-22 Common Stock 5214.0000 D Deferred Stock Units 2020-02-23 Common Stock 2208.0000 D Deferred Stock Units 2019-02-24 Common Stock 230.0000 D Deferred Stock Units 2022-02-28 Common Stock 5703.0000 D Stock Option (Right to Buy) 13.0800 2024-02-24 Common Stock 3000.0000 D Stock Option (Right to Buy) 16.3100 2025-02-23 Common Stock 16697.0000 D Stock Option (Right to Buy) 17.2600 2026-02-22 Common Stock 27675.0000 D Stock Option (Right to Buy) 24.5500 2027-02-28 Common Stock 25252.0000 D Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on January 2, 2015, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on January 2, 2014, which will continue to vest in one remaining installment on the anniversary of the date of grant. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 22, 2016, which will continue to vest in three remaining installments on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 23, 2015, which will continue to vest in two remaining installments on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 24, 2014, which will continue to vest in one remaining installment on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 28, 2017, which will continue to vest in four remaining installments on the anniversary of the date of grant. Grant to the reporting person of an option to purchase a 3,000 shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a 16,697 shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a 27,675 shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a 25,252 shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. eddypoa.txt /s/ Vance R. Brown, Attorney-in-fact 2018-04-03 EX-24 2 eddypoa.txt POWER OF ATTORNEY Know all by these present that the undersigned hereby constitutes and appoints each of Desiree Ralls-Morrison, Vance R. Brown, Jeff Mann, Ashley E. McGrane and Mai-Khoi Nguyen-Thanh signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of Boston Scientific Corporation (the "Company"), Forms 3, 4 and 5, and amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of the Company, Forms 144 in accordance with Rule 144 of the Securities Exchange Act of 1933, as amended and the rules and regulations thereunder; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities Act of 1933, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14th day of March, 2018. /s/ Jodi Euerle Eddy ________________ Jodi Euerle Eddy